Brooks Laboratories Limited

Brooks Laboratories Limited

Brooks Laboratories Limited has appointed Mr. Rajesh Mahajan as President - Trading with effect from July 17, 2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has entered into a binding Memorandum of Understanding (MoU) with Steriscience Specialties Private Limited and Brooks Steriscience Limited. The MoU records the commercial understanding among the parties in relation to the Company's proposed continuing investment in Brooks Steriscience Limited upon completion of the transaction. The MoU provides a value protection framework in respect of the Company's remaining investment, anti-dilution rights in respect of the existing business, principles governing capital requirements for the existing and future business lines, and certain interim rights and obligations of the parties during the term of the MoU.

Brooks Laboratories Limited

Brooks Laboratories Limited has received a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th June 2026. The certificate confirms that securities received from depository participants for dematerialisation were confirmed and listed on stock exchanges.

Brooks Laboratories Limited

Brooks Laboratories Limited has incorporated a wholly owned subsidiary, Abridge Speciality Limited, to expand its business.

Brooks Laboratories Limited

Brooks Laboratories Limited announced the closure of its trading window for Designated Persons and their immediate relatives, effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting and the opening of the trading window will be communicated later.

Brooks Laboratories Limited

Brooks Laboratories Limited announced it received a request from BSE Limited for additional details regarding its previously disclosed "Partial Sale of Equity Shares Held in Brooks Steriscience Limited" on June 19, 2026. The exchange specifically sought the Board Meeting commencement and conclusion times related to that transaction, in compliance with SEBI regulations. The company is submitting a revised disclosure to provide these required details. For investors, this update signifies regulatory scrutiny of the company's significant transaction and Brooks Laboratories' proactive adherence to disclosure norms.

Brooks Laboratories Limited

Brooks Laboratories Limited announced its board has approved the sale of 51,220 equity shares in Brooks Steriscience Limited. The shares will be sold to Steriscience Specialities Private Limited for a cash consideration of ₹20,760 per share. This transaction aggregates to approximately ₹106.33 crore, pending customary documentation and regulatory requirements. For investors, this represents a significant divestment by Brooks Laboratories, generating substantial cash flow which could be used for other strategic initiatives or strengthening its financial position.